Adherence to HAART among patients with HIV: Breakthroughs and barriers
- 1 June 2002
- journal article
- review article
- Published by Taylor & Francis in AIDS Care
- Vol. 14 (3) , 309-318
- https://doi.org/10.1080/09540120220123685
Abstract
Highly active antiretroviral therapy (HAART) has been a major breakthrough for the treatment of patients with HIV; however, adherence to treatment remains a formidable barrier. This paper evaluates the current state-of-the-science in adherence to HAART. Barriers to treatment success, determinants of adherence and interventions to improve adherence are reviewed. Overall, multifaceted interventions appear most promising. We conclude with recommendations to enhance clinical practice and improve treatment outcomes for patients with HIV. Despite substantial attention to adherence in recent years, much more remains to be done to understand and promote adherence to HAART.Keywords
This publication has 41 references indexed in Scilit:
- Trust and the Acceptance of and Adherence to Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Adherence to Pharmacological Interventions: Current Trends and Future DirectionsControlled Clinical Trials, 2000
- The relationship of disease severity, health beliefs and medication adherence among HIV patientsAIDS Care, 2000
- Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence InstrumentsAIDS Care, 2000
- Factors Affecting Adherence to Antiretroviral TherapyClinical Infectious Diseases, 2000
- Helping the urban poor stay with antiretroviral HIV drug therapyAmerican Journal of Public Health, 2000
- Predictors of Self-Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.Health Psychology, 2000
- Antiretroviral Therapy in AdultsJAMA, 2000
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998